Atezolizumab: Additional Phase II data

Roche reported additional data from the open-label, international Phase II BIRCH trial evaluating 1,200 mg IV atezolizumab every 3 weeks in 667 patients with PD-L1-positive locally advanced or metastatic NSCLC. Patients were stratified by PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (IC) with an immunohistochemistry (IHC) test and scored as TC 2 or 3 and IC 2 or 3. In patients with an IHC score of TC3 or IC3, atezolizumab as first-line treatment (n=65) led to an ORR of 26%, a 6-month PFS rate of 48% and a 6-month OS rate of 79%. In patients with an IHC score of TC3 or IC3, atezolizumab as second-line treatment (n=122) led to an ORR of 24%, a 6-month PFS rate of 34% and a 6-month OS rate of 80%. In patients with an IHC score of TC3 or IC3, atezolizumab as third-line or greater treatment (n=115) led to an ORR of 27%, a 6-month PFS rate of 39% and a 6-month OS rate of 75%. ...